Clinical trial
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV…
NCT00027742 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00027742 |
|---|---|
| Title | Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | pegylated interferon alfa, temozolomide |
| Start date | May 1, 2001 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: